These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32544576)

  • 1. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
    Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.
    Jing H; Hettich M; Gaedicke S; Firat E; Bartholomä M; Niedermann G
    J Immunother Cancer; 2019 Feb; 7(1):55. PubMed ID: 30808414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
    Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
    Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8
    Watson RA; Tong O; Cooper R; Taylor CA; Sharma PK; de Los Aires AV; Mahé EA; Ruffieux H; Nassiri I; Middleton MR; Fairfax BP
    Sci Immunol; 2021 Oct; 6(64):eabj8825. PubMed ID: 34597125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
    Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
    Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
    He K; Puebla-Osorio N; Barsoumian HB; Sezen D; Rafiq Z; Riad TS; Hu Y; Huang A; Voss TA; Leyton CSK; Schuda LJ; Hsu E; Heiber J; Cortez MA; Welsh JW
    J Exp Clin Cancer Res; 2024 Sep; 43(1):251. PubMed ID: 39218928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
    Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.
    Budimir N; Thomas GD; Dolina JS; Salek-Ardakani S
    Cancer Immunol Res; 2022 Feb; 10(2):146-153. PubMed ID: 34937730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
    Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
    J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity.
    Zheng M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade.
    Jagodinsky JC; Vera JM; Jin WJ; Shea AG; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarthy I; Allawi RH; Kim K; Harari PM; Sondel PM; Newton MA; Crittenden MR; Gough MJ; Miller JR; Ong IM; Morris ZS
    Sci Transl Med; 2024 Sep; 16(765):eadk0642. PubMed ID: 39292804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
    Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
    Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
    Holm JS; Funt SA; Borch A; Munk KK; Bjerregaard AM; Reading JL; Maher C; Regazzi A; Wong P; Al-Ahmadie H; Iyer G; Tamhane T; Bentzen AK; Herschend NO; De Wolf S; Snyder A; Merghoub T; Wolchok JD; Nielsen M; Rosenberg JE; Bajorin DF; Hadrup SR
    Nat Commun; 2022 Apr; 13(1):1935. PubMed ID: 35410325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8
    Qian J; Chen T; Wu Q; Zhou L; Zhou W; Wu L; Wang S; Lu J; Wang W; Li D; Xie H; Su R; Guo D; Liu Z; He N; Yin S; Zheng S
    Cancer Lett; 2020 Dec; 495():1-11. PubMed ID: 32949680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
    Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.